<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCB17A14-7B92-4327-AFFD-027228431198"><gtr:id>FCB17A14-7B92-4327-AFFD-027228431198</gtr:id><gtr:name>London North West Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCB17A14-7B92-4327-AFFD-027228431198"><gtr:id>FCB17A14-7B92-4327-AFFD-027228431198</gtr:id><gtr:name>London North West Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5712B094-4EB3-480B-B5D0-07EAEFB17C2F"><gtr:id>5712B094-4EB3-480B-B5D0-07EAEFB17C2F</gtr:id><gtr:firstName>Virginia</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Clowes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800435"><gtr:id>14B694DF-5015-4F3E-83F5-12933DC39403</gtr:id><gtr:title>The physiological and pathological functions of the hereditary spastic paraplegia protein spartin.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800435</gtr:grantReference><gtr:abstractText>The hereditary spastic paraplegias (HSPs) are a group of neurodegenerative genetic disorders affecting the axons of motor neurons, and causing affected people to develop a progressive lower limb spasticity and weakness. There may be associated neurological and non-neurological symptoms. The pathology of the HSPs is primarily confined to the axons, with axonal degeneration, leaving an intact cell body. Therefore studying these diseases at a cellular level is essential in determining the necessary cellular pathways required for axonal health. Whilst these insights will be important for the HSPs, it is also likely they will have a wider application and be relevant to other neurodegenerative conditions affecting axons, such as motor neuron disease and multiple sclerosis.

The main aim of this project is to understand the functions of the protein spartin, as loss of spartin causes the HSP Troyer syndrome. A further aim is to determine how absent spartin leads to axonal degeneration. This project will also provide insight into whether there are common mechanisms underlying the pathology of the HSPs in general. A greater understanding of these processes may then enable us to consider new treatments for these and related diseases.</gtr:abstractText><gtr:technicalSummary>This project is aimed at understanding the normal and pathological functions of spartin, loss of which causes hereditary spastic paraplegia (HSP). HSPs are genetic conditions in which long axons in the spinal cord show dying-back axonopathy, and so they are excellent models to understand axonal maintenance and degeneration. . 

Spartin is one of a group of endosomal HSP proteins. Abnormal endocytic function could cause HSP by dysregulating receptors controlling signaling pathways important for axons. We have shown that altered bone morphogenic protein (BMP) signaling is the cause of axonal abnormalities in Drosophila models of NIPA1 (an endosomal HSP protein) -HSP, and our preliminary data suggest that spartin regulates BMP signaling. I will confirm this, examine whether the mechanism is altered trafficking of BMP receptors, then examine whether the abnormal BMP signaling affects axonal growth pathways. 

We have also found that spartin interacts with AIP4, a protein implicated in the endosomal trafficking of the cytokine receptor CXCR4. I will examine whether spartin is necessary for normal trafficking of this receptor. We have identified interactions between spartin and two proteins that may be novel endosomal accessory proteins. I will confirm these interactions and examine their mechanistic relevance to BMP and CXCR4 membrane traffic.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>220808</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IHCAP</gtr:description><gtr:id>013C1CD5-3B08-4492-890F-5F24E817A9E6</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>54647e5a19e2a3.11538088-1</gtr:outcomeId><gtr:partnerContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place.</gtr:partnerContribution><gtr:piContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>RD14/057 NIHR Bioresources</gtr:description><gtr:id>A21C5B1C-2CC7-4295-8A46-DBAE6A795612</gtr:id><gtr:impact>No results issued at this stage.</gtr:impact><gtr:outcomeId>54647acb328711.31369725-1</gtr:outcomeId><gtr:partnerContribution>As above</gtr:partnerContribution><gtr:piContribution>Patients recruited and DNA samples submitted for exome and whole genome sequencing.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IMPACT study - Targeted prostate cancer screening in BRCA1/2 mutation carriers and controls</gtr:description><gtr:id>10A2D769-FDAC-42A0-9117-C954772E93D5</gtr:id><gtr:impact>Presentations and publications Sept 2007 - April 2011 (to be updated again in 2013)

ORAL
International
Genetic Predisposition to Prostate Cancer and Targeted Screening, Including The IMPACT Study
Invited Seminar Presentation at MD Anderson Cancer Center, Texas, April 2011

Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls
The Joint UK and Dutch Cancer Genetics Meeting Amsterdam March 2010, 

Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
IMPACT Collaborators' Meeting, Netherlands Cancer Institute, May 2009

Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
American Urological Association, Chicago, April 2009

National
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls
The UK Cancer Genetics Group meeting, London December 2010 

Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls
The UK Cancer Genetics Group meeting, London December 2009 

Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1 and BRCA2 Mutation Carriers and Controls.
Cancer Genetics Group Winter Meeting, London, December 2008


POSTERS
International
Bancroft E.K, Castro EC., Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
American Association of Cancer Research (AACR), Orlando, USA April 2011

Bancroft E.K, Castro EC., Page E, Eeles R.A
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
American Society of Human Genetics (ASHG), Washington, USA November 2010

Bancroft E.K, Castro EC., Page E, Eeles R.A
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
American Society of Human Genetics (ASHG), Hawaii, USA November 2009

Bancroft E.K, Castro EC., Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
The 11th International Conference on Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Toronto, Canada, April 2009

Mitra A.V., Bancroft E.K, Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
American Association of Cancer Research (AACR), Denver, USA April 2009

Bancroft E.K, Mitra A.V., Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
American Society of Human Genetics (ASHG), Philadelphia, USA November 2008

Mitra A.V., Bancroft E.K, Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
American Society of Human Genetics (ASHG), San Diego, USA November 2007

National

Castro EC., Bancroft E.K, Page E, Eeles R.A
The IMPACT study. Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. Cancer Genetics Group, Bristol, May 2011


Bancroft E.K., Page E.C., Castro E., Eeles R.A
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
National Cancer Research Institute (NCRI), October 2010

Bancroft E.K, Castro EC., Page E, Eeles R.A
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
The National Cancer Research Institute PROMPT meeting at The Cambridge Research Institute, 2010

Bancroft E.K., Page E.C., Castro E., Eeles R.A
Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 carriers and controls.
National Cancer Research Institute (NCRI), November 2009

Mitra A.V., Bancroft E.K, Page E, Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study 
The Institute of Cancer Research (ICR) Centenary Conference, June 2009

Mitra A, Bancroft E, Eeles, R 
Identification of men with a genetic predisposition to prostate cancer: targeted screening of BRCA1 and BRCA2 mutation carriers and controls. The IMPACT study - pilot results. 
NCRI Joint Annual Meeting, ICR, November 2008

Mitra A.V., Bancroft E.K., Eeles R.A
Results of the Pilot Study -Identification of men with a genetic predisposition to prostate cancer: targeted screening in BRCA1 and BRCA2 mutation carriers and controls: the IMPACT study
National Cancer Research Institute (NCRI), October 2008

Mitra A. V., Jhavar S, Bancroft E.K., Eeles R.A
Identification of men with a genetic predisposition to prostate cancer: targeted screening in BRCA1 and BRCA2 mutation carriers and controls: the IMPACT study
(British Association of Urological Surgeons) BAUS section of Oncology and the British Prostate Group, November 2007


Publications 

1. Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJUI (Sept, 2010, 14, doi: 10.1111/j.1464-410X.2010.09648.x.

2. Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge A, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman G, Evans DG, Blanco I, Mercer S, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Lilja H, Easton D, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, Cooper C, Eeles R, Neal, D. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PloS One 2010 Oct 13;5(10)

3. Mitra AV, Jameson C, Barbachano Y, et al. Elevated expression of Ki-67 identifies aggressive prostate cancer but does not distinguish BRCA1 and BRCA2 mutation carriers. Oncol Rep. 2010; 23(2):299-305.

4. Mitra A, Jameson C, Y. Barbachano, N. Sodha, Z. Kote-Jarai, A. Javed, E. Bancroft, A. Fletcher, Christopher S. Foster, C. Cooper, S. Peock, D. Easton, R. Eeles. Overexpression of TP53 is Associated with Aggressive Prostate Cancer but does not Distinguish Disease in BRCA1 or BRCA2 Mutation Carriers from a Control Group. The Open Prostate Cancer Journal 2009;2:38-45

5. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators, Eeles R, Foster CS. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009; 55: 696-704.

6. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D, Eeles R. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. British J Cancer 2008; 98: 502-7

7. Mercer C, Eccles D, Mitra A, Bancroft E, Eeles R. The Genetics of Prostate Cancer and the Potential for Targeted Screening: the IMPACT study. Oncology News, 2007; Volume 2 Issue 2, August/September.

8. Mitra A, Bancroft E, Eeles R, on behalf of the IMPACT Steering committee and collaborators. A review of targeted screening for prostate cancer: introducing the IMPACT Study. Br J Urol 2007; 99(6); 1350-1355.</gtr:impact><gtr:outcomeId>q8Yoz4CCMWr-1</gtr:outcomeId><gtr:partnerContribution>My fellow collaborators similarly recruited patients to the study and arranged for their annual follow-up. The Chief Investigator for this international study is Professor Ros Eeles, Royal Marsden Hospital, London.</gtr:partnerContribution><gtr:piContribution>I established the Cambridgeshire and East Anglian branch of this study in 2005. I was the IMPACT Principal Investigator for Cambridgeshire and East Anglia from 2005-2012. During this period I recruited all the local patients to the study and arranged for their annual follow-up clinic appointment with sample collection.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>Mendelian Disorders study</gtr:description><gtr:id>D730827A-1C40-4151-9507-CC0D8729831E</gtr:id><gtr:impact>None to date. Still awaiting sequencing results.</gtr:impact><gtr:outcomeId>54647d024c7543.20605670-1</gtr:outcomeId><gtr:partnerContribution>Patients recruited and DNA samples submitted for exome and whole genome sequencing.</gtr:partnerContribution><gtr:piContribution>Patients recruited and DNA samples submitted for exome and whole genome sequencing.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAARS</gtr:description><gtr:id>AE474758-F733-4A09-88B2-4D6AB397CE9E</gtr:id><gtr:impact>No outcomes yet.</gtr:impact><gtr:outcomeId>54647c56d8f102.60699602-1</gtr:outcomeId><gtr:partnerContribution>Have R&amp;amp;D and ethics approval enabling patients to be recruited to study.</gtr:partnerContribution><gtr:piContribution>Have R&amp;amp;D and ethics approval enabling patients to be recruited to study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Embrace</gtr:description><gtr:id>FD5D6E6E-E268-4CC2-A617-0A2F631A78F9</gtr:id><gtr:impact>Increased epidemiological data.</gtr:impact><gtr:outcomeId>54647e0052f7e2.70984025-1</gtr:outcomeId><gtr:partnerContribution>Patients recruited and epidemiological data supplied.</gtr:partnerContribution><gtr:piContribution>Patients recruited and epidemiological data supplied.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Deciphering Developmental Disorders</gtr:description><gtr:id>71F7E081-F9E9-449D-9BD2-94A43879BCAE</gtr:id><gtr:impact>Firth HV, Wright CF and DDD Study, The Deciphering Developmental Disorders (DDD) study.
Developmental medicine and child neurology 2011;53;8;702-3 PUBMED: 21679367</gtr:impact><gtr:outcomeId>sUyEFQqiv7i-1</gtr:outcomeId><gtr:partnerContribution>Other colleagues also recruit and phenotype patients for the study. The Wellcome Trust Sanger Institute then does microarray - CGH and whole exome sequencing on the DNA from each patient recruited. The aim of the study is to provide a genetic diagnosis for the recruited patients.</gtr:partnerContribution><gtr:piContribution>I recruit patients to this study. I also clinically phenotype the patients I recruit to this study.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London North West Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Breast and Ovarian cancer Study</gtr:description><gtr:id>123D030E-27B0-4313-877B-93952E0E9C70</gtr:id><gtr:impact>BRCA mutation testing in recruitees</gtr:impact><gtr:outcomeId>HFNop8Cdbqt-2</gtr:outcomeId><gtr:partnerContribution>N/A</gtr:partnerContribution><gtr:piContribution>I recruit patients to the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Insignia</gtr:description><gtr:id>940C3F84-DC3D-4359-AC1D-FBBD30760FD7</gtr:id><gtr:impact>none to date</gtr:impact><gtr:outcomeId>54647e9e0b9463.82763714-1</gtr:outcomeId><gtr:partnerContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place.</gtr:partnerContribution><gtr:piContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nipsigen</gtr:description><gtr:id>983102A6-FA85-486E-9AC3-C2721FDBD37D</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>54647c0b5af511.54014979-1</gtr:outcomeId><gtr:partnerContribution>Have R&amp;amp;D and ethics approval enabling patients to be recruited to study.</gtr:partnerContribution><gtr:piContribution>Have R&amp;amp;D and ethics approval enabling patients to be recruited to study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genpros</gtr:description><gtr:id>87C382B6-4511-4B92-A17C-6ACA0CA1EF3E</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>54647b88657612.18339732-1</gtr:outcomeId><gtr:partnerContribution>Patients recruited to study.</gtr:partnerContribution><gtr:piContribution>Patients recruited to study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Breast and Ovarian cancer Study</gtr:description><gtr:id>7E81E746-E653-4873-A07D-333B46F136C0</gtr:id><gtr:impact>BRCA mutation testing in recruitees</gtr:impact><gtr:outcomeId>HFNop8Cdbqt-1</gtr:outcomeId><gtr:partnerContribution>N/A</gtr:partnerContribution><gtr:piContribution>I recruit patients to the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sex trisomies</gtr:description><gtr:id>F6EEC52D-93E4-4061-9F12-11A2444DF7C6</gtr:id><gtr:impact>none to date.</gtr:impact><gtr:outcomeId>54647eeda381b2.79202820-1</gtr:outcomeId><gtr:partnerContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place. Patient recruitment has commenced.</gtr:partnerContribution><gtr:piContribution>Study open for recruitment. Local R&amp;amp;D and Ethics approval in place. patient recruitment has commenced.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Departmental Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D3A6B018-74CD-4FF8-8AB9-D3FE04D6A289</gtr:id><gtr:impact>Improved departmental understanding of the field of cell biology, and its importance in functional genomics, with particular relevance to the hereditary spastic paraplegias.

As above.</gtr:impact><gtr:outcomeId>FVKPLqeUm87</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cancer Genetics presentation to Breast cancer team at St Albans Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>67727AA6-442B-43F3-BE69-773105C78DD4</gtr:id><gtr:impact>We commenced a joint Genetics/Cancer clinic at St Albans City Hospital

Closer working relationship with Oncology colleagues, initiation of a dialogue in relation to future service development.</gtr:impact><gtr:outcomeId>54645a265107d7.25377275</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genomics presentation at Paediatric Neurology study day, the Lister Hospital, Stevenage</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2158BFA4-6038-49DA-AB88-79CC1FEB9769</gtr:id><gtr:impact>Education in relation to NHSE Genomic Medicine Centre tebids

Anticipated referrals for recruitment to 100,000 genomes study</gtr:impact><gtr:outcomeId>54645759f02bb8.70461164</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetics and Primary care</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DC1CC371-A8BD-4AD3-B0E6-B54EB41E9C40</gtr:id><gtr:impact>Talk generated a lot of interest in genetics in relation to primary care.

Follow-up emails to answer specific enquiries</gtr:impact><gtr:outcomeId>546458efdf2ab3.12256707</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Raymond and Beverly Sackler Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Raymond and Beverly Sackler Foundation</gtr:fundingOrg><gtr:id>78241434-C4B6-44A1-BF0A-AEC53A73EEE3</gtr:id><gtr:outcomeId>KtXn2K2Fcyw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0E5F2A99-2EDE-4869-BB65-316EA32B3171</gtr:id><gtr:title>The AAA ATPase spastin links microtubule severing to membrane modelling.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/170aa0fdd13208e304762d5fac9fa009"><gtr:id>170aa0fdd13208e304762d5fac9fa009</gtr:id><gtr:otherNames>Lumb JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_16566_26_21888932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1CBBC3D-FD64-4C37-A5B2-083705888BDD</gtr:id><gtr:title>Who needs microtubules? Myogenic reorganization of MTOC, Golgi complex and ER exit sites persists despite lack of normal microtubule tracks.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fccd8747b71a77e297fc6e0111d567a"><gtr:id>3fccd8747b71a77e297fc6e0111d567a</gtr:id><gtr:otherNames>Zaal KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16566_26_22216166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B97671CA-844D-41F8-84D2-309B3AF8DCF2</gtr:id><gtr:title>Endogenous spartin (SPG20) is recruited to endosomes and lipid droplets and interacts with the ubiquitin E3 ligases AIP4 and AIP5.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/753dc902d842c418da77010a4ba00bb0"><gtr:id>753dc902d842c418da77010a4ba00bb0</gtr:id><gtr:otherNames>Edwards TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>irJhG1ykfqA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11290A37-74EC-44D6-AE3E-1FD3BB931984</gtr:id><gtr:title>Overlapping molecular pathological themes link Charcot-Marie-Tooth neuropathies and hereditary spastic paraplegias.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b402a44f99ebbc88d2d50fc9c1b8b4f8"><gtr:id>b402a44f99ebbc88d2d50fc9c1b8b4f8</gtr:id><gtr:otherNames>Timmerman V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_16566_26_22285450</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800435</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>